| Detected | Trial | Change |
|---|---|---|
| 2026-05-28 | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors… |
date change Primary completion pushed: 2026-05-14 -> 2027-06-30 |
| 2026-05-28 | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors… |
date change Completion pushed: 2026-05-14 -> 2027-06-30 |
| 2026-05-23 | NCT04302025 A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages… |
Primary endpoint(s) modified |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05862285 | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La… | Cancer | Recruiting |
| NCT05170204 | A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| NCT04603807 | A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants… | Carcinoma, Non-Small-Cell Lung | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT03178552 | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT06528691 | Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With… | High Grade Glioma | Recruiting |
| NCT04302025 | A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages… | Non-small Cell Lung Cancer | Recruiting |
| NCT03994796 | Genetic Testing in Guiding Treatment for Patients With Brain Metastases | CDK Gene Mutation | Active, Not Recruiting |
| NCT04589845 | Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You… | Solid Tumors | Active, Not Recruiting |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors… | Breast Cancer | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT02650401 | Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or… | Solid Tumors | Active, Not Recruiting |
| Phase 1 | |||
| NCT05396859 | Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53… | Acute Myeloid Leukemia | Active, Not Recruiting |